Form 8-K AVEO PHARMACEUTICALS For: Mar 06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2015
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-34655 | 04-3581650 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
650 East Kendall Street Cambridge, Massachusetts |
02142 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (617) 299-5000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 | Results of Operations and Financial Condition. |
On March 6, 2015, AVEO Pharmaceuticals, Inc. (the Company) issued a press release announcing its results for the fourth quarter and year ended December 31, 2014. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Form 8-K and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01 | Other Events. |
On March 6, 2015, the Company issued a press release announcing the presentation of final results and a predefined biomarker analysis of its BATON-CRC (Biomarker Assessment of Tivozanib in Oncology-Colorectal Cancer) study. The full text of this press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits. |
(d) The following exhibits are included in this report:
Exhibit No. | Description | |
99.1 | Earnings press release issued by the Company on March 6, 2015 | |
99.2 | Press release entitled AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib versus Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC issued by the Company on March 6, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AVEO Pharmaceuticals, Inc. | ||
Date: March 6, 2015 | ||
By: | /s/ Michael Bailey | |
Michael Bailey | ||
President and Chief Executive Officer |
Exhibit 99.1
DRAFT NOT FOR IMMEDIATE RELEASE
AVEO Oncology Reports Full Year 2014 Financial Results
CAMBRIDGE, Mass. March 6, 2015 AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2014.
At the beginning of 2015, AVEO implemented several important changes designed to maximize the value of our portfolio of clinical stage products, said Michael Bailey, president and chief executive officer. Our approach to realizing this value is to leverage biomarker insights, including the promising new NRP-1 findings for tivozanib in metastatic colorectal cancer, and our demonstrated ability to advance our assets through partnerships. In support of these efforts, we have streamlined our organization to better align it with our clinically focused strategic needs going forward, extending our financial runway into the third quarter of 2016. We look forward to a productive 2015 as we work toward making progress in executing our strategy.
Recent Highlights
| Announced Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib versus Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC Today, AVEO announced the presentation of final results, including a predefined biomarker analysis, from the BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC). The presentation, titled Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial, will be presented in a poster session today at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference, taking place March 5-8, 2015, in Orlando, FL. |
| Named Michael P. Bailey as President and Chief Executive Officer In January 2015, AVEO announced that its board of directors appointed Michael P. Bailey as the Companys president and chief executive officer and has elected Mr. Bailey as a director. Mr. Bailey succeeds Tuan Ha-Ngoc, who was named chairman of AVEOs board of directors. |
| Announced Corporate Restructuring In January 2015, AVEO announced the elimination of its internal research function, as well as certain corporate support positions, to align resources with the Companys future strategic plans, focusing on advancement of its pipeline in the clinical setting and reducing corporate expenses. AVEO expects that the related severance and outplacement charges of approximately $4.5 million incurred in connection with the restructuring will be included in its results of operations for the first quarter of 2015. The reduction in force is expected to reduce compensation expenses annually by approximately $6 million and will further reduce AVEOs facilities requirements, by more than 80% of its current space, including the elimination of lab and vivarium needs. The Company announced today that it will exit its current facility by the end of May 2015. |
1
| Named Michael N. Needle, M.D. as Chief Medical Officer In January 2015, AVEO announced the appointment of Michael N. Needle, M.D., to the position of chief medical officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating and implementing clinical development strategies for advancement of the Companys proprietary and partnered clinical-stage programs. |
| Received Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application (MAA) to the European Medicines Agency In January 2015, AVEO announced that, in response to submission of a letter of intent, it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agencys centralized procedure. AVEO intends to evaluate the decision to submit a tivozanib Marketing Authorization Application (MAA) in Europe for the treatment of RCC. Confirmation of eligibility for submission is not predictive of the EMAs approval of a MAA. |
| Entered into Research and Exclusive Option Agreement with Ophthotech for Tivozanib for the Treatment of Ocular Diseases In November 2014, AVEO announced its entry into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of tivozanib outside of Asia for the potential treatment of non-oncologic diseases of the eye. The agreement enables AVEO to potentially realize additional value for tivozanib in an indication outside of cancer, while retaining oncology rights for further development through additional potential partnerships. |
Under the terms of the agreement, if Ophthotech exercises its option, AVEO would be eligible to receive, from Ophthotech, a total of up to $105.5 million in option fees and milestone payments, based on achievement of specified development, regulatory, sales and business goals, in addition to tiered, double digit royalties, up to the mid-teens, on net sales. This includes an upfront option fee of $500,000 received in the fourth quarter of 2014. Ophthotech is responsible for all research and development activities and costs, and upon exercise of its option, further development and commercialization activities and costs for tivozanib ocular indications. A percentage of all upfront, milestone and royalty payments received by AVEO are due to Kyowa Hakko Kirin as a sublicensing fee.
Full Year 2014 Financial Highlights
| AVEO ended 2014 with $52.3 million in cash and cash equivalents. |
| Total collaboration revenue for 2014 was approximately $18.1 million compared with $1.3 million for 2013. The increase was primarily due to recognition of an additional $13.7 million of previously deferred revenue as a result of the modification of the Companys arrangement with Biogen Idec. In addition, the Company recognized an additional $3.1 million of collaboration revenue in connection with the change in the estimated period of performance associated with the Companys collaboration with Astellas as a result of the termination of the agreement in August 2014. |
2
| Research and development (R&D) expense for 2014 was $38.3 million compared with $68.5 million for 2013. The decrease in R&D expense was primarily due to a reduction in personnel-related expenses following AVEOs June 2013 strategic restructuring as well as a decrease in external clinical trial, research, and medical affairs costs associated with reduced tivozanib clinical trial activity, and a decrease of costs relating to the manufacturing of ficlatuzumab, which was completed in 2013. |
| General and administrative (G&A) expense for 2014 was $18.6 million compared with $28.7 million for 2013.The decrease in G&A expense was primarily due to a reduction in personnel-related expenses following AVEOs June 2013 strategic restructuring as well as a decrease in marketing and consulting costs due to termination of work related to tivozanib pre-commercialization activities. |
| Restructuring and lease exit expense for 2014 was $11.7 million compared with $8.0 million for 2013. The expenses incurred during 2014 relate to costs associated with partially vacating and subsequently terminating the agreement for the Companys leased space. The expenses incurred during 2013 relate to severance and employee benefits incurred as part of the June 2013 strategic restructuring. |
| Net loss for 2014 was $52.7 million, or a net loss of $1.01 per basic and diluted share compared with net loss of $107.0 million or a net loss of $2.10 per basic and diluted share for 2013. |
Updated Financial Guidance
Based on its current operating plan, the Company expects its $52.3 million in cash resources as of December 31, 2014 will be sufficient to fund operations into the third quarter of 2016.
About AVEO
AVEO Oncology (NASDAQ: AVEO) is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where significant unmet medical needs exist. AVEOs proprietary Human Response Platform has delivered unique insights into cancer and related disease biology that AVEO is seeking to leverage in the clinical development strategy of its therapeutic candidates. For more information, please visit the companys website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, target, potential, objective, could, should, seek, or the negative of
3
these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: the Companys strategy for future growth; the Companys strategy and ability to rebuild shareholder value; the Companys estimated restructuring charges and realized cost reductions from the reduction in its facilities requirement; anticipated benefits from the restructuring; statements about payments that may be received by AVEO under both the option agreement and any future license agreement with Ophthotech; AVEOs estimates regarding its financial runway; and the Companys future growth and long-term success. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to: AVEOs ability to successfully implement and manage its restructuring and obtain the benefits it expects to derive from the reduction in its workforce and internal research functions; AVEOs ability to execute on its business strategy and enter into and maintain new strategic partnerships and collaboration agreements, including the risk that Ophthotech does not elect to exercise its option to enter into a license agreement with AVEO to further develop tivozanib; the risk of any breach, event of default under, or acceleration of the payment terms of AVEOs loan agreement with Hercules; AVEOs ability to successfully enroll and complete clinical trials of its product candidates; AVEOs ability to demonstrate to the satisfaction of the FDA, EMA or other equivalent foreign regulatory agencies, the safety, efficacy and clinically meaningful benefit of its product candidates; AVEOs ability to achieve and maintain compliance with all regulatory requirements applicable to its product candidates; AVEOs ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates and technologies; developments and expenses related to AVEOs ongoing shareholder litigation and SEC inquiry; AVEOs ability to raise the substantial additional funds required to achieve its goals; unplanned capital requirements; adverse general economic and industry conditions; competitive factors; and those risks discussed in the section titled Risk Factors included in AVEOs most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and in its other filings with the SEC. The forward-looking statements in this press release represent AVEOs views as of the date of this press release. AVEO anticipates that subsequent events and developments will cause its views to change. However, while AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEOs views as of any date subsequent to the date of this press release.
4
AVEO Pharmaceuticals, Inc.
Consolidated Balance Sheet Data
(In thousands)
(Unaudited)
December 31, | December 31, | |||||||
2014 | 2013 | |||||||
Assets | ||||||||
Cash, cash equivalents and marketable securities |
$ | 52,306 | $ | 118,506 | ||||
Accounts receivable |
2,341 | 984 | ||||||
Prepaid expenses and other current assets |
4,481 | 9,429 | ||||||
Property and equipment, net |
11,295 | 14,140 | ||||||
Other assets |
239 | 3,287 | ||||||
|
|
|
|
|||||
Total assets |
$ | 70,662 | $ | 146,346 | ||||
|
|
|
|
|||||
Liabilities and stockholders equity | ||||||||
Accounts payable and accrued expenses |
$ | 17,527 | $ | 17,501 | ||||
Total loans payable |
20,652 | 19,205 | ||||||
Total deferred revenue |
768 | 18,392 | ||||||
Total deferred rent |
10,569 | 20,072 | ||||||
Other liabilities |
540 | 1,238 | ||||||
Stockholders equity |
20,606 | 69,938 | ||||||
|
|
|
|
|||||
Total liabilities and stockholders equity |
$ | 70,662 | $ | 146,346 | ||||
|
|
|
|
5
AVEO Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
For the Three Months | For the Years | |||||||||||||||
Ended December 31, | Ended December 31, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
Collaboration revenue |
$ | 115 | $ | 323 | $ | 18,123 | $ | 1,293 | ||||||||
Operating expenses: |
||||||||||||||||
Research and development |
8,702 | 11,889 | 38,254 | 68,468 | ||||||||||||
General and administrative |
3,104 | 4,499 | 18,589 | 28,712 | ||||||||||||
Restructuring and lease exit |
1,302 | 4 | 11,729 | 8,017 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
13,108 | 16,392 | 68,572 | 105,197 | |||||||||||||
Loss from operations |
(12,993 | ) | (16,069 | ) | (50,449 | ) | (103,904 | ) | ||||||||
Other income and expense: |
||||||||||||||||
Other (expense) income, net |
(37 | ) | (3 | ) | 66 | (123 | ) | |||||||||
Interest expense |
(866 | ) | (676 | ) | (2,388 | ) | (3,127 | ) | ||||||||
Interest income |
2 | 23 | 32 | 125 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Other expense, net |
(901 | ) | (656 | ) | (2,290 | ) | (3,125 | ) | ||||||||
Net loss |
$ | (13,894 | ) | $ | (16,725 | ) | $ | (52,739 | ) | $ | (107,029 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted net loss per share |
||||||||||||||||
Net loss |
$ | (0.27 | ) | $ | (0.32 | ) | $ | (1.01 | ) | $ | (2.10 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Weighted average number of common shares outstanding |
51,802 | 51,546 | 52,289 | 50,928 | ||||||||||||
|
|
|
|
|
|
|
|
Company, Media and Investor Contact:
David Pitts, Argot Partners
(212) 600-1902
6
Exhibit 99.2
DRAFT NOT FOR IMMEDIATE RELEASE
AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS
with Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients with
Advanced CRC
Results Presented at AACR Tumor Angiogenesis and Vascular Normalization Conference
AVEO to Host Conference Call Today, March 6, 2015 at 8:00 am ET
CAMBRIDGE, Mass. Mar 6, 2015 AVEO Oncology (NASDAQ: AVEO) today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC). The presentation, titled Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial, will be presented in a poster session today at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference, taking place March 5-8, 2015, in Orlando, FL. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and activity against all three VEGF receptors.
The BATON-CRC study enrolled a total of 265 patients randomized 2 to 1 to receive tivozanib in combination with mFOLFOX6 (n=177) compared to bevacizumab and mFOLFOX6 (n=88) as first-line treatment in patients with advanced metastatic CRC. A key objective of the BATON-CRC study is the assessment of prospectively defined biomarkers that may be predictive of response in selected patient subpopulations. Among these, patients with low neuropilin-1 (NRP-1) showed an improved progression free survival (PFS) versus patients with high NRP-1 in both treatment arms, supporting the value of NRP-1 as a potential prognostic marker for angiogenesis inhibitors. Further, patients with serum NRP-1 levels below the median demonstrated longer PFS when treated with tivozanib (17.9 months, n=52), compared to bevacizumab (11.2 months, n=28) (HR=0.380, p=0.0075), suggesting NRP-1 may have potential as a predictive biomarker of tivozanib activity relative to bevacizumab. Patients with high serum NRP-1 had PFS of 7.3 months and 7.5 months for the tivozanib and bevacizumab arms, respectively. With only 21 deaths in the NRP-1 low group upon study termination, no conclusion could be reached in an analysis of overall survival.
An earlier, pre-specified interim futility analysis determined that tivozanib was unlikely to demonstrate superiority to bevacizumab in the primary endpoint of PFS in the intent to treat population (ESMO 2014), resulting in discontinuation of the study. The results presented today are the final results, and include five additional months of study conduct and patient follow-up beyond the data cutoff for the interim futility analysis. In the intent to treat population, the tivozanib and bevacizumab combinations demonstrated comparable results for PFS, the primary
1
endpoint (9.8 months and 9.5 months for tivozanib and bevacizumab, respectively, HR=0.908, p=0.598), and overall response rate (46.9% and 43.2%, for tivozanib and bevacizumab, respectively), while demonstrating comparable safety. The most common toxicities included diarrhea, nausea, fatigue, neutropenia and hypertension. Serious adverse events were reported for 46.3% of patients in the tivozanib group and 48.3% in the bevacizumab group.
Where NRP-1 expression is low, the tumor appears to rely more heavily on the VEGF pathway and become more susceptible to anti-VEGF therapies, such as bevacizumab or tivozanib, an observation seen across several tumor types, including breast, gastric, colorectal and renal cell cancers, said Al B. Benson III, MD, FACP, Professor of Medicine at the Feinberg School of Medicine, Associate Director for Clinical Investigations at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and principal investigator of the study. Results from the BATON-CRC study are consistent with these observations. Further, the increase in PFS for patients treated with tivozanib compared to bevacizumab is both interesting and encouraging. I believe that these findings warrant further study in a prospectively defined trial of patients with low serum NRP-1 metastatic colorectal cancer.
These results underscore tivozanibs activity and differentiating properties, including the potential benefit of a more complete anti-angiogenesis blockade in selected patient populations, said Michael Needle, MD, chief medical officer of AVEO. We believe these data suggest a promising new development path forward in a significant patient population.
A copy of the poster presentation is available on AVEOs website at www.aveooncology.com.
Todays Conference Call and Webcast Information
The AVEO management team will host a conference call today, March 6, at 8:00 am (ET). The call can be accessed by dialing 1-877-280-4954 (domestic) or 1-857-244-7311 (international) five minutes prior to the start of the call and providing the passcode 38640881. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 54500453. The replay will be available for two weeks from the date of the live call.
The live webcast of the conference call can be accessed by visiting the investors section of the AVEO website at www.aveooncology.com. A replay of the webcast will be archived on the AVEO website for two weeks following the call.
About Colorectal Cancer
The American Cancer Society estimates that more than 130,000 men and women in the United States will be diagnosed with colorectal cancer (CRC) and nearly 50,000 will die of the disease in the United States in 2015.1 CRC is the third most commonly diagnosed cancer in both men and women and the third leading cause of cancer death in the United States. In Europe, it is estimated that almost 180,000 men and women are diagnosed with CRC and that nearly 80,000 die from the disease each year.2
2
About Tivozanib
Tivozanib is an oral, once-daily, investigational vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications. Tivozanib has been evaluated in several tumors types, including renal cell, colorectal and breast cancers.
About AVEO
AVEO Oncology (NASDAQ: AVEO) is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where significant unmet medical needs exist. AVEOs proprietary Human Response Platform has delivered unique insights into cancer and related disease biology that AVEO is seeking to leverage in the clinical development strategy of its therapeutic candidates. For more information, please visit the companys website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, target, potential, could, should, seek, or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about potential strategic options for the development of tivozanib and the expected beneficial properties of tivozanib, including its potential to provide a more complete anti-angiogenesis blockade. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to: AVEOs ability to execute on its business strategy, including its ability to enter into and maintain new strategic partnerships and collaboration agreements; AVEOs ability to successfully enroll and complete clinical trials and preclinical studies of its product candidates; AVEOs ability to demonstrate to the satisfaction of the FDA, EMA or other equivalent foreign regulatory agencies, the safety, efficacy and clinically meaningful benefit of its product candidates; AVEOs ability to demonstrate in later clinical trials positive results that may be observed in earlier-stage clinical trials; AVEOs ability to achieve and maintain compliance with all regulatory requirements applicable to its product candidates; AVEOs ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates and technologies; developments and expenses related to AVEOs ongoing shareholder litigation and SEC inquiry; AVEOs ability to raise the substantial additional funds required to achieve its goals; adverse general economic and industry conditions; competitive factors; and those risks discussed in the section titled Risk Factors included in AVEOs most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and in its other filings with the SEC. The forward-looking statements in this press release represent AVEOs views as of the date of this press release. AVEO anticipates that subsequent events and developments will cause its views to change. However, while AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEOs views as of any date subsequent to the date of this press release.
3
References
1 | American Cancer Society. Available at: |
http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/index |
2 | Ferlay, J. et al. European Journal of Cancer, Volume 46, Issue 4, 765 781, 2009 |
Company, Media and Investor Contact:
David Pitts, Argot Partners
(212) 600-1902
4
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Company announcement no 6/2024 - Finance Calendar update
- Wolters Kluwer’s MediRegs triumphs in 2024 BIG Innovation Awards
- Completion of Largest Capacity GMP Run Marks New Standard in Biologics Manufacturing
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!